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Background: Alcohol withdrawal delirium (AWD) is associated with significant morbidity and mortality. Pellagra
(niacin deficiency) can be a cause of delirium during alcohol withdrawal that may often be overlooked.
Objectives: We present a three-patient case series of pellagrous encephalopathy (delirium due to pellagra)
presenting as AWD.
Methods: We provide a brief review of pellagra’s history, data on pellagra’s epidemiology, and discuss pellagra’s
various manifestations, particularly as related to alcohol withdrawal. We conclude by providing a review of existing
guidelines on the management of alcohol withdrawal, highlighting that they do not include pellagrous
encephalopathy in the differential diagnosis for AWD.
Results: Though pellagra has been historically described as the triad of dementia, dermatitis, and diarrhea, it
seldom presents with all three findings. The neurocognitive disturbance associated with pellagra is better
characterized by delirium rather than dementia, and pellagra may present as an isolated delirium without any other
aspects of the triad.
Discussion: Although endemic pellagra is virtually eradicated in Western countries, it continues to present as
pellagrous encephalopathy in patients with risk factors for malnutrition such as chronic alcohol intake,
homelessness, or AIDS. It may often be mistaken for AWD. Whenever pellagra is suspected, treatment with oral
nicotinamide (100 mg three times daily for 3–4 weeks) prior to laboratory confirmation is recommended as an
inexpensive, safe, and potentially life-saving intervention.
Keywords: Alcohol withdrawal delirium, Pellagra, Pellagrous encephalopathy, Niacin deficiency, Vitamin B3
deficiency, Delirium tremensAlcohol withdrawal delirium and pellagrous
encephalopathy
Treatment-resistant alcohol withdrawal is a serious clin-
ical problem due to its high morbidity and mortality [1].
Studies and case reports over the past several years de-
scribe patients hospitalized for alcohol withdrawal who
develop delirium and receive high doses of benzodiaze-
pines [1-3]. These patients with alcohol withdrawal delir-
ium (AWD) tend to have costly and prolonged hospital
stays despite, and likely also because of, aggressive* Correspondence: mark.oldham@bmc.org
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02118, USA
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distribution, and reproduction in any mediumpsychopharmacologic treatment involving not only large
quantities of benzodiazepines but also other sedatives
such as propofol or barbiturates [4].
Alcohol withdrawal delirium, a synonym for delirium
tremens (DTs), often poses a diagnostic dilemma given
the many possible etiologies of delirium combined with
the patient’s inability to provide a precise history. Delir-
ium with autonomic instability in alcohol-dependent
inpatients requires diligent clinical care. When a patient
fails to improve with escalating doses of sedatives, it is
essential for clinicians to broaden the differential diagno-
sis and consider other medical conditions that may be
complicating the clinical picture. For example, alcohol-
dependent patients may be prone to dehydration,Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Pellagra-related terminology
Term Definition
Aniacinosis early term for alcohol-related pellagra
Antidermatitis factor early term for niacin
Antipellagra factor early term for niacin
Parapellagra early term for alcohol-related pellagra
Pellagra* from pelle agra, Italian for “rough skin”
Pellagra-preventive
(P-P) factor
early term for niacin
Pellagra sine pellagra pellagra without dermatologic
manifestations
Pellagrin one afflicted with pellagra
Pellagrosari asylums where pellagrins would
receive care
Pellagrous (rarely, pellagrinous) of or related to pellagra
Pellagrous encephalopathy delirium due to pellagra
Pellagrous psychosis delirium due to pellagra
Pseudopellagra early term for alcohol-related pellagra
*Selected synonyms: alpine scurvy, mayidism, St. Ignatius itch, Lombardy
erysipelas.
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fection, pancreatitis, and nutritional deficiencies. Vita-
min B deficiencies in particular are well documented
among alcohol-dependent individuals—thiamine defi-
ciency being the most widely described in the medical
literature [5]. However, many patients with AWD con-
tinue to do poorly despite supportive care and treatment
with sedatives and thiamine supplementation.
Patients admitted for alcohol withdrawal almost uni-
versally receive thiamine on admission; however, the role
of niacin deficiency in AWD has largely been ignored
for several decades [6]. Although endemic niacin defi-
ciency has essentially been eradicated in most Western
countries [7], pellagra may account for a significant por-
tion of AWD [5,8-10].
In this report, we first review the history of pellagra,
present data on its epidemiology, and outline its classical
and atypical presentations particularly in the context of
alcohol withdrawal. Next, we examine modern case
reports of pellagra in urban settings and present three
new case reports of pellagra presenting as AWD. Finally,
we review existing guidelines for the management of al-
cohol withdrawal and discuss implications for clinical
practice. We advocate that pellagra should be considered
on the differential diagnosis for all patients with chronic
alcohol dependence and others at risk of malnutrition
such as the homeless and those positive for HIV.
History of pellagra
Don Gaspar Casal of Oviedo, Spain, first described pel-
lagra in 1735 [11]. The disease was named pellagra in
1771 by Frapolli due to its dermatologic manifestations
(Table 1) [12]. From its earliest descriptions, mention
has been made of pellagra’s connection with poverty and
malnourishment. Pellagra’s association with alcohol de-
pendence has been known for more than two centuries
[11,13]. In 1926, Goldberger’s work implicated vitamin B
deficiency as the cause of pellagra [14]. More than a dec-
ade later, Koehn and Elvehjem [15] were the first to iso-
late niacin when they demonstrated it could cure black
tongue (the canine model of pellagra) in dogs. As a re-
sult of widespread fortification with niacin of grains and
cereals in the US food supply, endemic pellagra has
nearly been eradicated [16]. The rarity of pellagra in the
general population may lead clinicians to exclude it from
the differential diagnosis, even in malnourished patients.
The role of niacin in metabolism
Niacin, also known as vitamin B3, is water-soluble and
does not have any appreciable stores in the body. Symp-
tomatic niacin deficiency can present as soon as 60 days
after insufficient dietary intake [17]. Niacin principally
functions as a coenzyme or cosubstrate in a vast array of
biological redox reactions in the forms of nicotinamideadenine dinucleotide hydrogen (NADH) and nicotina-
mide adenine dinucleotide phosphate hydrogen
(NADPH) [18]. One milligram of niacin is equal to one
niacin equivalent (NE); it is naturally found in meats as
nicotinamide and in plants as nicotinic acid [17], where
1 mg of each represents one NE [19]. Cooking accounts
for no more than a 25% reduction in niacin owing to
niacin’s heat stability [17]. In the absence of sufficient
dietary niacin, 60 mg of the amino acid tryptophan can
be converted into one NE [19], but this conversion
requires adequate thiamine, riboflavin, pyridoxine, and
NADP [20]. Protein contains a little over 1% tryptophan,
so roughly 6 gm of protein can yield one NE [18]. The
daily recommended allowance of NE is 16 for men, 14
for women, and 18 for pregnant women [19]. Table 2
provides a list of NE content in common foods [21].Epidemiology
Although clinicians are often and appropriately con-
cerned about Wernicke-Korsakoff syndrome (WKS) in
patients with chronic alcohol dependence due to the po-
tential long-term sequelae, the often overlooked pellag-
rous encephalopathy should also be considered. This
expanded differential should make intuitive sense clinic-
ally, as the presence of one B vitamin deficiency almost
certainly implies the presence of a deficiency of other
water-soluble vitamins. Dastur et al. drew serum and
cerebrospinal fluid (CSF) levels of B vitamins (B1, 2, 3, 5,
6, 12, and folate) in 59 chronically malnourished patients
with both alcohol dependence and neurological findings
(peripheral neuropathy and/or delirium) [5]. They found
significantly decreased levels of all B vitamins tested
Table 2 Niacin equivalent (NE*) content in common foods
per 100 g†
Milk (whole or nonfat) 0.1 mg Hamburger
(cooked)
4.8 mg
Apricots (dry) 3.3 mg Cured ham (cooked) 4.2 mg
Apricots (raw) 0.8 mg Tuna fish (canned) 12.8 mg
Orange juice 0.2 mg Salmon (raw) 7.2 mg
Tomato juice 0.8 mg Turkey 8.0 mg
Bran flakes
breakfast cereal






Brown rice 4.6 mg Carrot (raw) 0.5 mg
White rice 1.6 mg Spinach
(raw or cooked)
0.6 mg
Whole wheat bread 3.0 mg Baked beans 0.5 mg
White bread 2.2 mg Green peas (frozen) 1.9 mg
Roasted peanuts 16.2 mg Tomato ketchup 2.2 mg
Peanut butter 16.2 mg Beer (4% alcohol by volume) 0.2 mg
*One NE is equal to 1 mg niacin as either nicotinamide or nicotinic acid.
†From Burton BT: Human Nutrition, 3rd Ed. [21].
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CSF compared with 69 healthy controls [5]. In general,
malnutrition implies deficiency of more than one
nutrient.
Widespread underdiagnosis of pellagra may distort the
few epidemiological data that exist on the condition, con-
tributing to a misleadingly low reported prevalence of
0.3% based on premortem diagnosis in a necropsy case
series [22]. In one study, niacin deficiency was found in
37% of long-term care patients in Ontario [23]; in an-
other, 15% of women in Malmo, Sweden, had suboptimal
niacin levels [24]. The postmortem findings of Ishii and
Nishihara [9] provocatively suggest that the prevalence of
pellagra may be as high as 27% in patients with alcohol
dependence who died during hospitalization, which—as
suggested in Cook’s review [8]—would represent a large
burden of undiagnosed but treatable disease.Figure 1 Courtesy of Richard Johnson, MD, Department of
Dermatology, Massachusetts General Hospital, Boston, MA
USA, 2012.Clinical presentations: Classical and atypical
pellagra
Pellagra has been historically described by the “three
Ds”—dermatitis, diarrhea, and dementia. A fourth D,
death, may result if left untreated [25]. Importantly, one
rarely sees this clinical triad in its entirety, and although
pellagra is named for its rash, the dermatologic findings
are not a sine qua non of pellagra. Dermatologic findings
are frequently absent in pellagra—a condition known as
pellagra sine pellagra (Table 1) [9,26-29]. When present,
the dermatologic findings are generally characterized by
an erythematous rash in sun-exposed skin. The portion
of the rash involving the neck has been described asCasal’s necklace. The dermatitis ranges from obvious
scaly erythema to subtle changes that are often mistaken
for the photo-damage typically seen in the elderly
(Figure 1). Gastrointestinal (GI) involvement is thought
to be due to generalized inflammation of the alimentary
canal, with symptoms including stomatitis, glossitis, nau-
sea, vomiting, constipation, abdominal pain, and ultim-
ately, intractable diarrhea [30]. The diarrhea itself can
contribute to ongoing malnourishment.
The neurocognitive impairment historically described
as the third D, dementia, is more consistent with delir-
ium than dementia. In pellagrous encephalopathy, elec-
troencephalography (EEG) generally reveals diffuse
slowing, particularly in the theta range, as in five of six
patients described by Spivak and Jackson [29]; in all 16
patients with pellagra on whom an EEG was obtained in
another case series [10]; and in Case two described
below. For example, the 1918 Statistical Manual for the
Use of the Institutions for the Insane (a diagnostic tool
preceding the first edition of the Diagnostic and Statis-
tical Manual of Mental Disorders [DSM]) records:
The mental disturbances which are apparently most
intimately connected with pellagra are certain
delirious or confused states (toxic-organic-like
reactions) arising during the course of a severe
pellagra [31].
Oldham and Ivkovic Addiction Science & Clinical Practice 2012, 7:12 Page 4 of 9
http://www.ascpjournal.org/content/7/1/12Thus, the 3 Ds of pellagra might be better thought of as
dermatitis, diarrhea, and delirium. Other neurological in-
volvement includes the development of diverse extrapyr-
amidal symptoms [9,29]. In particular, all 22 patients with
alcoholic pellagra described by Serdaru et al. [10] pre-
sented with gegenhalten (also known as paratonic rigidity),
which is characterized by resistance to movement propor-
tional to the force applied. Other findings may include
myoclonus, ataxia, and various cerebellar signs. Postmor-
tem pathologic findings of alcoholic pellagrous encephal-
opathy involve diffuse, bilaterally symmetric, central
chromatolysis of neurons (ballooning of neuronal cell bod-
ies), although these findings are most consistent in the
pontine nuclei [23]. Brain imaging is nonspecific in pel-
lagra; some patients may exhibit global atrophy associated
with chronic alcohol use or changes suggestive of other
concomitant alcohol-related conditions such as WKS or
Marchiafava-Bignami disease [10,32].
Causes of niacin deficiency
Causes of niacin deficiency include inadequate oral in-
take (e.g., starvation resulting from homelessness, anor-
exia nervosa, kwashiorkor, or particular diets such as
those of maize or the jowar diet); malabsorptive states
(e.g., Crohn’s or Hartnup disease); states of excess loss
(e.g., hemodialysis or peritoneal dialysis); or metabolic
derangements (e.g., carcinoid syndrome, diets rich in the
amino acid leucine, or prolonged use of levodopa, iso-
niazid, ethionamide, or 6-mercaptopurine) [19,33]. Pel-
lagra itself can perpetuate further malnutrition due to
GI effects [30,33].
Niacin deficiency in the alcohol-dependent
population
Chronically alcohol-dependent patients are at high risk
for nutritional deficiencies due to their often poor diets.
For a subset of alcohol-dependent patients, alcohol





N1-methylnicotinamide/creatinine in 24 h (mg/g)
adults (men; and nongravid and 1st trimester women) <0.5
2nd trimester women <0.6
3rd trimester women <0.8
2-pyridone/N1-methylnicotinamide <0.5
*Niacin assays require plasma obtained using a lavender-topped tube with ethylene
light, heat, and humidity [36], laboratories often require that samples be wrapped i
†Urinary assays more accurately assess niacin intake than confirm the presence of n
laboratory confirmation of niacin deficiency [35].nutrient intake is sufficient, nutrient absorption may be
impaired due to alcohol’s direct (via damage to duodenal
villi) or indirect (via pancreatic insufficiency or vitamin
deficiency) effects on the GI system [34]. Ishii and Nishi-
hara [9] suggested that clinicians ought to have a high
suspicion for pellagra in patients with alcohol depend-
ence, particularly those with unexplained persistent
mental status changes, neurological symptoms, or GI
distress.
Diagnosis and treatment of niacin deficiency
The provisional diagnosis of pellagra can be made on
clinical grounds alone [33], although testing for niacin
levels or urinary metabolites of niacin is available
(Table 3). With treatment, the dermatologic and GI
symptoms generally resolve within 48 hours. As such,
the diagnosis of pellagra is often confirmed by this rapid
resolution of symptoms ([35] and case reports, below).
The treatment response of neurocognitive symptoms is
more variable; they may resolve within days, or a patient
may experience persisting neurocognitive deficits.
The World Health Organization recommends treating
pellagra with nicotinamide, either 300 mg per day orally
in divided doses or 100 mg per day parenterally in
divided doses, for 3–4 weeks [35]. Although these doses
are significantly less than those used for dyslipidemias
(1–2 gm or the equivalent 1000–2000 NEs daily), re-
placement with nicotinamide is often recommended to
avoid the flushing commonly caused by niacin [18,38].
Replacement, not supplementation
Multivitamins, B-complex vitamins, and common nutri-
tional supplements (see Case two below) supply insuffi-
cient amounts of NEs for prompt replacement.
Common multivitamins contain between 10 and 40 NEs;
B-complex vitamins generally contain 50 NEs; and cer-
tain common nutritional supplements provided at hospi-
tals contain 3 NEs each. When the diagnosis of pellagralites
nt Low Adequate High
<0.5 0.5− 8.45 >8.45
0.5− 1.59 1.6− 4.29 ≥4.3
0.6− 1.99 2− 4.99 ≥5
0.8− 2.49 2.5− 6.49 ≥6.5
0.5− 0.99 1− 4 >4
diaminetetraacetic acid (EDTA). Despite niacin's stability when exposed to
n foil to protect them from light and freezing immediately [37].
iacin deficiency. As such, serum niacin would be appropriate test for
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for symptom resolution. Patients with niacin deficiency
should receive at least 300 NEs daily for replacement,
which is more than typical supplementation dosing.
Moreover, when the diagnosis is unclear, administration
of replacement-level dosing of NE to a patient without
pellagra would be unlikely to cause adverse side effects
given that side effects due to niacin are generally mild
up to the maximum recommended dose of 6 gm daily
when prescribed for hyperlipidemias [38].
We suspect that several weeks of lower,
supplementation-dose niacin—from the cumulative niacin
intake of a patient’s diet or vitamin supplements—may
slowly replace niacin stores and result in resolution of
clinical signs and symptoms. However, if this “inadvertent
cure” does occur, it likely prolongs morbidity and hospital
course. For this reason, when pellagra is suspected, it is
advisable to begin treatment with nicotinamide before
awaiting laboratory confirmation.
Recent case reports: Special populations
Pellagra remains an often overlooked problem in the
context of alcohol dependence and malnutrition in
developed countries, particularly because endemic pel-
lagra has been virtually eradicated [7,16]. Prior commen-
taries have overemphasized pellagra’s eradication in
industrialized countries [6,23,39], a fact cited by several
authors [8,26,28,29,33,40,41]. However, several case
reports in recent decades, including those described
below, highlight the importance of maintaining a high
index of suspicion for this potentially fatal but treatable
condition [26,28,29,41-44]. Despite such case reports
and series, guidelines on the management of alcohol
withdrawal do not include niacin deficiency as a poten-
tial cause of delirium in patients with alcohol-
withdrawal symptoms.
The diagnosis of pellagra may be missed when a clin-
ician looks for malnutrition only in those patients who
appear undernourished. Obese patients are an example
of seemingly nourished patients who may, nonetheless,
be deficient in vital nutrients. A case report of an obese
patient illustrated this with its example of pellagra sine
pellagra masquerading as odynophagia [26].
Homeless populations deserve special mention, as
their typically poor diet and high rates of alcohol use
disorders lead to an increased risk of developing pel-
lagra. Kertesz’s report of pellagra in two homeless men
represents a rare modern report of pellagra among
homeless populations in a developed urban environ-
ment; on the rarity of such case reports, the article
reads, “To my knowledge, no report to date has
described pellagra in contemporary homeless people,
despite the fact that the homeless are subject to relevant
vulnerabilities of alcoholism, social dislocation, andirregular access to food” [28]. Such reports are a timely
reminder that pellagra continues to exist in certain mal-
nourished populations in industrialized countries. More-
over, recent reports have suggested that pellagra may be
increasing in alcohol-dependent populations and among
those positive for HIV in both developing and developed
countries [42].
Maintaining a high index of suspicion for pellagra is
important given its atypical presentations and varied ap-
pearance. As shown in Spivak and Jackson’s study of 18
patients [29], only four patients had the classic triad of
dermatitis, diarrhea, and dementia (or more accurately,
as described above, delirium). Strikingly, five out of 18
patients had neurocognitive changes as the sole mani-
festation of pellagra; no diarrhea or dermatitis was
present. Similarly, an early three-patient case series by
Zimmerman [45] found two patients with only neuro-
logical signs to suggest the presence of pellagra. In fact,
Jolliffe et al. [46] suggested that pellagra sine pellagra in
the context of alcohol withdrawal may develop so rap-
idly that dermatologic changes do not have time to
occur. Physicians, therefore, should take special caution
not to miss this diagnosis in a patient with suspected
AWD without skin or GI findings. Looking exclusively
for the classic triad is likely to lead clinicians to overlook
the diagnosis.
A recent report by Brown [33] illustrates an example of
an atypical case in which an alcohol-dependent man was
admitted for an unusual dermatitis; he later developed
mental status changes but had no GI symptoms. Intraven-
ous multivitamins had not been initiated with this patient
until hospital day 18 when niacin deficiency was sus-
pected. Within two days of initiating niacin treatment, the
skin lesions improved markedly, supporting the diagnosis
of pellagra. As suggested by Das et al., “Physicians should
be aware of such cases and should treat any ‘sick’ [alcohol-
dependent] person with unexplained skin, neuropsychi-
atric changes or gastrointestinal complaints with safe,
inexpensive doses of niacin” [40].
In a post-mortem case series of chronically alcohol-
dependent Japanese patients, Ishii and Nishihara [9]
found pathological changes on necropsy consistent with
pellagra in 20 of 74 patients. Of note, sake, the soy-
based alcoholic beverage common in Japan, has essen-
tially no niacin content; common beer in the US has a
nominal 0.2 mg per 100 g or 0.7 mg per 12 oz [21]. They
advised suspecting pellagra in chronic alcohol-
dependent patients in the absence of skin lesions that
may otherwise prompt consideration of the diagnosis: “It
is emphasized that whenever chronic alcoholics exhibit
certain mental, neurological, or gastrointestinal symp-
toms, one should strongly suspect pellagra” [9].
In view of the above reports, one wonders how many
alcohol-dependent patients in the community may be
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[47]. When mild dermatitis is present, it may be attribu-
ted to routine sun exposure or diagnosed as an inciden-
tal dermatologic finding (see Case one below). Further,
patients with AWD present a particular diagnostic di-
lemma: the differential diagnosis for delirium in the pa-
tient with chronic alcohol dependence receiving high
doses of sedatives is broad. Increasing doses of benzo-
diazepines can contribute to delirium [48], making it
even more difficult to establish the cause of a patient’s
altered mental status. By promptly suspecting and treat-
ing pellagra, a clinician may avoid this confusing cycle
altogether. The following case reports illustrate how eas-
ily pellagra can be overlooked.
Case one
Mr. A, a 51-year-old man with HIV, hepatitis C, alcohol
dependence of 30 years duration, and past alcohol with-
drawal seizures and DTs, was admitted to the hospital
for alcohol detoxification. He had not been taking anti-
retroviral medications for HIV prior to presentation. He
reported drinking one quart of vodka daily for the past
two months. On presentation, his blood alcohol level
was 269 mg/dL, and he complained of nausea, diarrhea,
and abdominal pain. He had poor dentition and diffuse
epidermal scaling with erythema of exposed skin, attrib-
uted to chronic seborrheic dermatitis. Routine admission
laboratory tests and imaging were unremarkable.
On admission, Mr. A received vitamin supplements
(thiamine, folate, and a multivitamin), oral diazepam
(20 mg every four hours), and intravenous (IV) loraze-
pam (8 mg every two hours). On hospital day two, his
scores on the Clinical Institute Withdrawal Assessment
(CIWA)—a common bedside measure that assesses signs
and symptoms of alcohol withdrawal—ranged from
17–20. He was transferred to the medical intensive
care unit (MICU) due to increasing agitation and com-
bativeness, and he received a more aggressive regimen
of lorazepam. On hospital day three, he was disor-
iented and responding to internal stimuli. Additionally,
he exhibited signs of autonomic instability leading the
primary team to initiate an IV lorazepam infusion for
suspected DTs. Over the next 24 hours he received
nearly 600 mg of lorazepam.
Dermatology was consulted to evaluate his rash, which
was described as “dull, dark red erythema with overlying
loose scale in photodistribution on scalp, face, neck,
upper chest and dorsal lower arms. Eruption . . . spares
clothing-bearing areas of the chest and upper arms.”
Dermatology considered it to be a possible photoallergic
reaction to Bactrim, which had been started on admis-
sion, so the medication was held. By hospital day four,
his mental status and rash had not improved. Due to his
prominent skin findings, confusion, and malnutrition,the diagnosis of pellagra was considered, and oral niacin
was started at 100 mg by mouth every six hours. His
rash was mildly improved the following day, and by hos-
pital day six his rash was nearly resolved. Lorazepam
was tapered over the following days, and his mental sta-
tus gradually improved to baseline. By hospital day 18
his rash had resolved, and he was discharged.
Upon discharge, he resumed drinking alcohol and did
not continue taking any prescribed medications. He was
readmitted for alcohol detoxification one month later, at
which time he demonstrated a similar photodistributed
erythematous rash. On day two of his second hospital
stay, dermatology was consulted. They provisionally
diagnosed pellagra given the reappearance of the rash.
The diagnosis was presumed to be confirmed when his
rash readily cleared again upon restarting niacin.
Case two
Ms. B, a 54-year-old Caucasian woman with alcohol de-
pendence (one and a half pints of whiskey and five
glasses of wine daily for “many years”) and esophageal
dysmotility presented to the emergency department with
diarrhea, vomiting, a 30-pound weight loss over six
months, and altered mental status. She was admitted for
medical detoxification from alcohol and evaluation of
her GI complaints. An abdominal computerized tomog-
raphy (CT) scan was strongly suggestive of cirrhosis,
and routine laboratory tests were remarkable for macro-
cytic anemia, thrombocytopenia, hypoalbuminemia, and
elevated aspartate and alanine aminotransferase levels.
Over the first two days, Ms. B received fluid repletion
and vitamin supplementation with thiamine, folate, and
multivitamins. She also received high-dose diazepam.
She spent two nights in the MICU due to her altered
mental status and the high doses of sedatives she was re-
ceiving. Over the next two weeks, she received a total of
nearly 1600 mg of diazepam and 150 mg of lorazepam.
Psychiatry was consulted on hospital day 19 for contin-
ued delirium four days after last receiving any sedatives.
Clinical evaluation revealed a resting tremor and
prominent, disabling ataxia. Examination of extraocular
muscles was unremarkable. She was somnolent, oriented
to person only, perseverative on nonsensical ideas, and
inattentive. Her speech was impoverished and her affect
labile. She appeared to be poorly nourished and had lim-
ited oral intake.
Brain magnetic resonance imaging was notable for
small periventricular and subcortical white matter fluid-
attenuated inversion recovery (FLAIR) hyperintensities
which most likely represented a sequela of chronic small
vessel disease. Electroencephalography revealed diffuse
slow-waves consistent with encephalopathy.
Daily exams over the following week revealed contin-
ued disorientation. Her affect remained labile, and she
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sis of pellagra was considered more than a week later
due to her poor nutritional status, delirium, ataxia, per-
sistent diarrhea, and glossitis. The patient was started on
niacin 100 mg by mouth three times daily. Within three
days, her delirium had resolved, and her ataxia had
improved markedly. Her affect was pleasant and appro-
priately reactive. She was discharged to a subacute re-
habilitation facility within four days of starting niacin.
Case three
Mr. C, a 61-year-old Caucasian man with severe chronic
alcohol dependence and alcohol-related cardiomyopathy,
had been drinking one half-gallon of rum every 1–2 days
and had very poor oral intake. He had no past DTs or al-
cohol withdrawal seizures. On admission to the hospital
for alcohol withdrawal, he received a chlordiazepoxide
taper as well as daily thiamine and folate. On hospital day
5, he completed the chlordiazepoxide taper and received
5 mg of haloperidol intramuscularly for agitation. By day
7, he continued to exhibit fluctuating disorientation and
had an episode of hypoxia of unclear etiology.
Physical examination revealed a thin elderly man with
an erythematous scaly rash on his nasal bridge and mild
hyperpigmentation of skin on sun-exposed areas. Nystag-
mus, tremor, and asterixis were absent. He was disoriented
to place and date, and his gait was ataxic. His blood oxy-
gen saturation was in the upper 90s on room air, and his
vital signs were unremarkable. Chest X-ray was negative
for an acute process or vascular congestion.
A diagnosis of pellagra was suspected. While awaiting
results of the serum niacin level, treatment with oral
nicotinamide 100 mg three times a day was started.
Within two days, his mental status has improved re-
markably. He was much more consistently oriented, and
the scaly rash on his nasal bridge had cleared. The diag-
nosis of pellagra was confirmed with a nondetectable la-
boratory niacin level.
Case report discussion
In each of these cases, pellagra was considered relatively
late in the patient’s hospital stay despite multiple risk fac-
tors for malnutrition in each patient. All three had long
histories of alcohol intake. The first two patients received
escalating doses of benzodiazepines for the management
of AWD. All received thiamine, folate, and multivitamin
supplementation early but failed to improve clinically. In
each case, psychiatry was consulted due to delirium. All
three patients responded quickly and dramatically to
therapeutic doses of niacin, the third of which had niacin
deficiency confirmed by laboratory testing. (It is important
to note that, although pellagra was likely present in each
case, delirium is often multifactorial, and other causes
may have contributed to the delirium attributed to AWD).Maintaining a broad differential diagnosis is critical in the
management of delirium.
Treatment guidelines for the management of
alcohol withdrawal
In 2004, the American Society of Addiction Medicine
(ASAM) developed evidence-based practice guidelines
for the management of AWD [49]. As the guidelines
were based on a review of the medical literature, the
pharmacologic agents recommended were limited to
those that have already been studied for the manage-
ment of AWD. Benzodiazepines and other sedative hyp-
notics, neuroleptics, and thiamine were among those
recommended as evidence-based treatment. Cost and
safety were taken into consideration for inclusion in the
treatment guidelines. Despite the low cost and large
therapeutic window of niacin, no prospective study has
been performed to examine its efficacy in reducing mor-
bidity and mortality in AWD; hence, it is not mentioned
in ASAM’s guidelines.
Treatment guidelines for alcohol withdrawal devel-
oped by the National Institute on Alcohol Abuse and
Alcoholism, as outlined by Myrick and Anton [50], dis-
cuss the roles of thiamine and folate in alcohol with-
drawal. Of note, folate replacement is not uncommon
in the treatment of alcohol withdrawal despite the lack
of clear clinical benefit. Treatment guidelines on alco-
hol withdrawal presented by the American Psychiatric
Association mention WKS specifically and make brief
mention of B-complex vitamin supplementation rather
than replacement [51]. Guidelines by the National Insti-
tute for Health and Clinical Excellence provide a review
of acute and chronic medical complications of alcohol
use (of which they list 12 and 28, respectively) yet do not
mention pellagra [52]. Besides these guidelines, several
clinical reviews on the management of alcohol with-
drawal do not mention pellagra despite emphasizing the
role of thiamine in preventing WKS [8,53-57].
Implications for clinical practice
Physicians should include pellagra in the differential
diagnosis of all patients with risk factors for malnutri-
tion, including chronic excessive alcohol intake, home-
lessness, or AIDS. It should be particularly considered in
any patient with prolonged alcohol withdrawal or AWD.
The focus of this article has been pellagrous encephalop-
athy presenting in the context of alcohol withdrawal be-
cause of the significant morbidity and mortality of AWD
and because consideration of pellagra has been excluded
from current treatment guidelines of alcohol withdrawal
Treatment guidelines for the management of alcohol
withdrawal should specifically advise the inclusion of
niacin deficiency on the differential diagnosis for all
cases of suspected AWD.
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http://www.ascpjournal.org/content/7/1/12The 3 Ds of pellagra would be more accurately concep-
tualized as dermatitis, diarrhea, and delirium. Moreover, it
should be emphasized that pellagra often presents with
delirium alone, with no other elements of the triad, par-
ticularly in patients with alcohol withdrawal. Patients in
whom pellagra is suspected should receive replacement-
level doses of nicotinamide. Therapy should consist of oral
nicotinamide (at least 300 mg daily in divided doses) or
parenteral nicotinamide (at least 100 mg daily in divided
doses) for 3–4 weeks. Prompt initiation of nicotinamide
replacement without waiting for laboratory confirmation
of niacin deficiency is advised.
Future research on the prevalence of pellagra in chronic-
ally alcohol-dependent patients, especially in those hospi-
talized with AWD, would help to clarify the prevalence of
pellagra in certain high-risk populations. Should further
evidence indicate that pellagra accounts for a significant
portion of AWD, perhaps nicotinamide should be consid-
ered for routine administration to patients presenting for
alcohol detoxification. In an era of cost-cutting measures,
treatment with nicotinamide is an inexpensive interven-
tion that has the potential to shorten pellagra-related hos-
pital stays. The high morbidity and mortality of AWD
make the inclusion of nicotinamide a cheap, safe, viable,
and potentially lifesaving intervention.
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